GlassScriptPhysician profile
Ilya I Fishman
NPI 1346434578
$2,476.95
in general payments reported to CMS, 2019-2025
24 companies · $422 in 2025
The $422 reported for 2025 was more than what 76% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $507 · 2022: $651 · 2023: $388 · 2024: $509 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $482.41 | 2021-2024 | Xarelto |
| Pfizer INC. | $425.54 | 2021-2025 | |
| Novo Nordisk INC | $274.11 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Novartis Pharmaceuticals Corporation | $228.35 | 2021-2024 | |
| Exact Sciences Corporation | $223.50 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $116.36 | 2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $102.29 | 2021-2022 | |
| Axsome Therapeutics, INC. | $61.38 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $59.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $59.27 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.73 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $49.86 | 2024 | Gemtesa |
| Lilly USA, LLC | $47.61 | 2021-2023 | Trulicity, Mounjaro |
| Lundbeck LLC | $47.30 | 2023 | Rexulti |
| Abbott Laboratories | $40.58 | 2023-2024 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.43 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $30.60 | 2022-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $27.36 | 2024 | |
| Ibsa Pharma INC. | $23.25 | 2021 | |
| Astellas Pharma US INC | $20.89 | 2022 | |
| Esperion Therapeutics, INC. | $19.25 | 2024 | Nexletol |
| Masimo Corporation | $16.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.14 | 2022 | |
| Abbvie INC. | $13.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.